ARDX
Ardelyx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.78
+1.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 450.9M | 407.3M | 333.6M | 124.5M | 52.2M |
| Cost of Revenue | 27.2M | 42.6M | 50.6M | 17.8M | 4.1M |
| Gross Profit | 423.7M | 364.7M | 283.1M | 106.7M | 48.0M |
| Operating Expenses | |||||
| R&D Expense | 85.4M | 68.5M | 52.3M | 35.5M | 35.2M |
| SG&A Expense | 373.7M | 337.2M | 258.7M | 134.4M | 76.6M |
| General & Admin Expense | — | — | — | — | 76.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 459.1M | 405.7M | 311.0M | 169.9M | 111.8M |
| Cost and Expenses | 486.3M | 448.3M | 361.6M | 187.7M | 115.9M |
| Operating Income (EBIT) | (35.5M) | (41.0M) | (27.9M) | (63.3M) | (63.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 27.4M | 28.4M | 20.1M | 8.9M | 5.1M |
| Net Interest Income | (27.4M) | (28.4M) | (20.1M) | (8.9M) | (5.1M) |
| Other Non-Op Income/Expense | (20.0M) | (19.7M) | (10.9M) | (2.2M) | (3.4M) |
| Non-Operating Income (excl Interest) | (7.4M) | (8.7M) | (9.2M) | (6.6M) | (1.6M) |
| EBT (Pre-Tax Income) | (55.5M) | (60.6M) | (38.9M) | (65.5M) | (67.2M) |
| Income Tax Expense | 227.0K | 969.0K | 266.0K | 547.0K | 8.0K |
| Bottom Line | |||||
| Net Income | (55.7M) | (61.6M) | (39.1M) | (66.1M) | (67.2M) |
| Earnings from Cont. Ops | (55.7M) | (61.6M) | (39.1M) | (66.1M) | (67.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (55.7M) | (61.6M) | (39.1M) | (66.1M) | (67.2M) |
| Per Share | |||||
| Basic EPS | ($0.23) | ($0.26) | ($0.17) | ($0.30) | ($0.42) |
| Diluted EPS | ($0.23) | ($0.26) | ($0.17) | ($0.30) | ($0.42) |
| Revenue Per Share | $1.82 | $1.69 | $1.42 | $0.57 | $0.33 |
| Shares | |||||
| Basic Shares Outstanding | 248.1M | 241.0M | 235.2M | 219.3M | 158.7M |
| Diluted Shares Outstanding | 248.1M | 241.0M | 235.2M | 219.3M | 158.7M |
| Profitability Metrics | |||||
| EBITDA | (23.8M) | (29.2M) | (16.7M) | (55.4M) | (61.0M) |
| D&A | 4.3M | 3.1M | 2.1M | 1.3M | 1.1M |
| EBIT | (28.0M) | (32.2M) | (18.8M) | (56.6M) | (62.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026